What is PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020?

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020 is Malaysia P.U. (A), cited as P.U. (A) 257 2020, currently marked in force and first recorded in 2020.

Is PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020 still in force?

Yes — PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020 is currently in force.

When did PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020 take effect?

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020 was first recorded in 2020.

How many sections does PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020 have?

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020 contains 2 sections.

Where can I read the official version of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020?

The official text of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020 is published at lom.agc.gov.my.

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020 (No. 257)

Seksyen 1

Perintah ini bolehlah dinamakan Perintah Racun (Pindaan Senarai Racun) 2020.

Seksyen 2

Pindaan Jadual Pertama

(a)

dalam Senarai Racun—

(i)

dengan memotong butiran “Abciximab” dan butir-butir yang berhubungan dengannya;

(ii)

dengan memasukkan selepas butiran “Abatacept” dan butir-butir yang berhubungan dengannya butiran yang berikut:

P.U. (A) 257 3

Names

Exempt

Group A

Group B

Group C

Group D

“Abemaciclib

-

All preparations”;

(iii)

dengan memotong butiran “Adalimumab” dan butir-butir yang berhubungan dengannya;

(iv)

dengan memasukkan selepas butiran “Alcuronium chloride” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Alectinib

-

All preparations”;

(v)

dengan memotong butiran “Alemtuzumab” dan butir-butir yang berhubungan dengannya;

(vi)

dengan memotong butiran “Alirocumab” dan butir-butir yang berhubungan dengannya;

(vii)

dengan menggantikan butiran “Allergens (in test kits)” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

P.U. (A) 257 4

Names

Exempt

Group A

Group B

Group C

Group D

“Allergens

-

(1)

All preparations for therapeutic use

(2)

In-vivo diagnostic test kits

-

(1)

All preparations unless in Group B

(2)

Preparation for laboratory use”;

(viii)

di bawah “Antihistamines; the following:”, dengan memasukkan selepas butiran “Cyproheptadine” butiran

“Desloratadine”;

(ix)

dengan memasukkan selepas butiran “Antimony; its chlorides, oxides, sulphides, antimonates, antimonites; organic compounds of antimony” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Apalutamide

-

All preparations”;

P.U. (A) 257 5

(x)

dengan memotong butiran “Atezolizumab” dan butir-butir yang berhubungan dengannya;

(xi)

dengan memasukkan selepas butiran “Baclofen; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Name

Exempt

Group A

Group B

Group C

Group D

“Baloxavir marboxil

-

All preparations”;

(xii)

dengan memasukkan selepas butiran “Barbituric acid and other substances structurally derived therefrom; their compounds; their salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Baricitinib

-

All preparations”;

(xiii)

dengan memotong butiran “Basiliximab” dan butir-butir yang berhubungan dengannya;

(xiv)

dengan memasukkan selepas butiran “Beclamide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

P.U. (A) 257 6

Names

Exempt

Group A

Group B

Group C

Group D

“Bedaquiline

-

All preparations”;

(xv)

dengan memotong butiran “Belimumab” dan butir-butir yang berhubungan dengannya;

(xvi)

dengan memotong butiran “Bevacizumab” dan butir-butir yang berhubungan dengannya;

(xvii)

dengan memotong butiran “Blinatumomab” dan butir-butir yang berhubungan dengannya;

(xviii)

dengan memotong butiran “Brentuximab” dan butir-butir yang berhubungan dengannya;

(xix)

dengan memasukkan selepas butiran “Brexpiprazole” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Brigatinib

-

All preparations”;

(xx)

dengan memotong butiran “Canakinumab” dan butir-butir yang berhubungan dengannya;

P.U. (A) 257 7

(xxi)

dengan memasukkan selepas butiran “Carfilzomib” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Cariprazine

-

All preparations”;

(xxii)

dengan memotong butiran “Certolizumab” dan butir-butir yang berhubungan dengannya;

(xxiii)

dengan memotong butiran “Cetuximab” dan butir-butir yang berhubungan dengannya;

(xxiv)

dengan memasukkan selepas butiran “Chloroform” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“4-Chloromethcathinone

-

All preparations”;

(xxv)

dengan menggantikan butiran “Citicoline” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

P.U. (A) 257 8

Names

Exempt

Group A

Group B

Group C

Group D

“Citicoline

-

All preparations for parenteral administration

-

All preparations unless in Group B

Cladribine

-

All preparations”;

(xxvi)

dengan memasukkan selepas butiran “Clozapine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Cobicistat

-

All preparations”;

(xxvii)

dengan memotong butiran “Dacliximab” dan butir-butir yang berhubungan dengannya;

(xxviii)

dengan memotong butiran “Daratumumab” dan butir-butir yang berhubungan dengannya;

(xxix)

dengan memotong butiran “Denosumab” dan butir-butir yang berhubungan dengannya;

P.U. (A) 257 9

(xxx)

dengan memasukkan selepas butiran “Dimethyl fumarate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Dimethylone

-

All preparations”;

(xxxi)

dengan memotong butiran “Efalizumab” dan butir-butir yang berhubungan dengannya;

(xxxii)

dengan memasukkan selepas butiran “Eltrombopag” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Elvitegravir

-

All preparations”;

(xxxiii)

dengan memasukkan selepas butiran “Eptifibatide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

P.U. (A) 257 10

Names

Exempt

Group A

Group B

Group C

Group D

“Erdosteine

-

All preparations”;

(xxxiv)

dengan memasukkan selepas butiran “Ertapenem sodium” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Ertugliflozin

-

All preparations”;

(xxxv)

dengan memasukkan selepas butiran “Etanercept” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Etelcalcetide

-

All preparations”;

(xxxvi)

dengan memotong butiran “Evolocumab” dan butir-butir yang berhubungan dengannya;

P.U. (A) 257 11

(xxxvii)

dengan memasukkan selepas butiran “4-Fluoroamphetamine (4-FA) (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“3-Fluoromethcathinone

-

All preparations”;

(xxxviii)

xxxviii

dengan memasukkan selepas butiran “Fluoxetine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Fluralaner

-

All preparations”;

(xxxix)

dengan memasukkan selepas butiran “Glaphenine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

P.U. (A) 257 12

Names

Exempt

Group A

Group B

Group C

Group D

“Glecaprevir

-

All preparations”;

(xl)

dengan memasukkan selepas butiran “Glucose” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Glutathione

-

All preparations for parenteral administration

-

All preparations unless in Group C”;

(xli)

dengan memotong butiran “Golimumab” dan butir-butir yang berhubungan dengannya;

(xlii)

dengan memotong butiran “Idarucizumab” dan butir-butir yang berhubungan dengannya;

(xliii)

dengan memotong butiran “Infliximab” dan butir-butir yang berhubungan dengannya;

(xliv)

dengan memasukkan selepas butiran “Iomeprol” dan butir-butir yang berhubungan dengannya butiran yang berikut:

P.U. (A) 257 13

Names

Exempt

Group A

Group B

Group C

Group D

“Iopamidol

-

All preparations”;

(xlv)

dengan memasukkan selepas butiran “Irinotecan; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Isavuconazole

-

All preparations”;

(xlvi)

dengan memasukkan selepas butiran “Ivermectin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Ixazomib

-

All preparations”;

P.U. (A) 257 14

(xlvii)

dengan memasukkan selepas butiran “Leptazol” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Lercanidipine

-

All preparations

Letermovir

-

All preparations”;

(xlviii)

dengan memasukkan selepas butiran “Liraglutide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Lisdexamfetamine

-

All preparations”;

(xlix)

dengan menggantikan butiran “Local anaesthetics; the following: their salts; their homologues and analogues;

their molecular compounds:” serta butiran di bawahnya dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

P.U. (A) 257 15

Names

Group A

Group B

Group C

Group D

“Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:

All preparations containing local anaesthetics unless in Group

B, Group C or

Group D

All preparations in pharmaceutic al dosage forms unless in Group C

(1)

All preparations in pharmaceutical dosage form for topical use in the nose, eyes and ears or external use

(2)

Suppositories, lozenges and pastilles

(3)

Preparations in the form of cartridges for dental use containing 2% or less of local anaesthetic

Preparations for laboratory use”;

P.U. (A) 257 16

Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or the derivatives of these acids;

their salts

Benzocaine

Bupivacaine

Butyl aminobenzoate

Cinchocaine

Diperodon

Etidocaine

Lignocaine

Levobupivacaine

Mepivacaine

Orthocaine

P.U. (A) 257 17

Oxethazaine

Phenacaine

Phenodianisyl

Prilocaine

Ropivacaine

Tetracaine

(l)

dengan memasukkan selepas butiran “Lonazolac; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Lonoctocog alfa

-

All preparations”;

(li)

dengan memasukkan selepas butiran “Lopinavir” dan butir-butir yang berhubungan dengannya butiran yang berikut:

P.U. (A) 257 18

Names

Exempt

Group A

Group B

Group C

Group D

“Lorlatinib

-

All preparations”;

(lii)

dengan memasukkan selepas butiran “Lovastatin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Lubiprostone

-

All preparations”;

(liii)

dengan memasukkan selepas butiran “10-Methoxydeserpidine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

P.U. (A) 257 19

Names

Exempt

Group A

Group B

Group C

Group D

“5-Methoxy-N,N-diisopropyltryptamine

-

All preparations”;

(liv)

dengan memasukkan selepas butiran “5-Methoxy-3, 4 methylenedioxyamphetamine (MMDA) (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“5-Methoxy-N,N-methylisopropyltryptamine

-

All preparations

2-(2-Methoxyphenyl)-1-(1-

pentylindol-3-yl)ethanone (JWH-250)

-

All preparations

4-Methyl-alpha-pyrrolidinobutiophenone

-

All preparations”;

P.U. (A) 257 20

(lv)

dengan memasukkan selepas butiran “Methyl bromide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“4-Methylbuphedrone

-

All preparations”;

(lvi)

dengan memasukkan selepas butiran “Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl] carbonyl}amino)-3-

methylbutanoate (5F-AMB)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Methyl (2S)-2-({1-[(4-

fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-

3-methylbutanoate (AMB-FUBINACA)

-

All preparations”;

P.U. (A) 257 21

(lvii)

dengan memasukkan selepas butiran “Moclobemide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Modafinil

-

All preparations”;

(lviii)

dengan memasukkan selepas butiran “Monensin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Monoclonal antibody;

includes the followings:

Abciximab

Adalimumab

Alemtuzumab

Alirocumab

-

All preparations”;

P.U. (A) 257 22

Atezolizumab

Basiliximab

Belimumab

Benralizumab

Bevacizumab

Blinatumomab

Brentuximab

Brodalumab

Canakinumab

Certolizumab

Cetuximab

Dacliximab

Daratumumab

Denosumab

Efalizumab

Emicizumab

Erenumab

Evolocumab

Golimumab

Guselkumab

Idarucizumab

P.U. (A) 257 23

Infliximab

Ixekizumab

Mepolizumab

Natalizumab

Necitumumab

Nivolumab

Obinutuzumab

Ofatumumab

Omalizumab

Palivizumab

Panitumumab

Pembrolizumab

Pertuzumab

Ramucirumab

Ranibizumab

Risankizumab

Rituximab

Sarilumab

Secukinumab

Tocilizumab

Trastuzumab

P.U. (A) 257 24

Ustekinumab

Vedolizumab

(lix)

dengan menggantikan butiran “Narcotic substances, the following: their isomers (whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers (whenever the existence of such esters or ethers is possible); the salts of their esters and ethers -” dengan butiran

“Narcotic substances; the following:";

(lx)

dengan memotong butiran “Natalizumab” dan butir-butir yang berhubung dengannya;

(lxi)

dengan memotong butiran “Necitumumab” dan butir-butir yang berhubung dengannya;

(lxii)

dengan memasukkan selepas butiran “Nepafenac” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Neratinib

-

All preparations”;

P.U. (A) 257 25

(lxiii)

dengan menggantikan butiran “Nitric Oxide” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Nitric Oxide

-

Preparations in the form of medicinal gas for therapeutic use

-

All preparations unless in Group B”;

(lxiv)

dengan memotong butiran “Nivolumab” dan butir-butir yang berhubung dengannya;

(lxv)

dengan memotong butiran“Obinutuzumab” dan butir-butir yang berhubung dengannya;

(lxvi)

dengan memotong butiran “Ofatumumab” dan butir-butir yang berhubung dengannya;

(lxvii)

dengan memotong butiran “Omalizumab”dan butir-butir yang berhubung dengannya;

(lxviii)

dengan memotong butiran “Palivizumab” butir-butir yang berhubung dengannya;

(lxix)

dengan memotong butiran “Panitumumab” butir-butir yang berhubung dengannya;

P.U. (A) 257 26

(lxx)

dengan memotong butiran“Pembrolizumab” butir-butir yang berhubung dengannya;

(lxxi)

dengan memotong butiran “Pertuzumab” butir-butir yang berhubung dengannya;

(lxxii)

dengan menggantikan butiran “Phenytoin and other substances structurally derived from hydantoin; their salts”

dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Phenytoin and other substances structurally derived from hydantoin;

their salts

-

All preparations unless exempted

-

Cosmetic which is notified under the Control of

Drugs and

Cosmetics

Regulations 1984

containing derivatives of hydantoin”;

(lxxiii)

dengan memasukkan selepas butiran “Phosphorus white, yellow, red or black” dan butir-butir yang berhubungan dengannya butiran yang berikut:

P.U. (A) 257 27

Names

Exempt

Group A

Group B

Group C

Group D

“Pibrentasvir

-

All preparations”;

(lxxiv)

dengan memotong butiran “Ramucirumab” dan butir-butir yang berhubung dengannya;

(lxxv)

dengan memotong butiran “Ranibizumab” dan butir-butir yang berhubung dengannya;

(lxxvi)

dengan memasukkan selepas butiran “Ribavirin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Ribociclib

-

All preparations”;

(lxxvii)

dengan memasukkan selepas butiran “Riociguat” dan butir-butir yang berhubungan dengannya butiran yang berikut:

P.U. (A) 257 28

Names

Exempt

Group A

Group B

Group C

Group D

“Ripasudil

-

All preparations”;

(lxxviii)

lxxviii

dengan memotong butiran “Rituximab” dan butir-butir yang berhubung dengannya;

(lxxix)

dengan memotong butiran “Secukinumab” dan butir-butir yang berhubung dengannya;

(lxxx)

dengan memasukkan selepas butiran “Selexipag” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

"Semaglutide

-

All preparations

“Semduramicin

-

All preparations”;

(lxxxi)

dengan menggantikan butiran “Sildenafil; its salts” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

P.U. (A) 257 29

Names

Exempt

Group A

Group B

Group C

Group D

“Sildenafil

-

All preparations

Siltuximab

-

All preparations”;

(lxxxii)

dengan memasukkan selepas butiran “Simeprevir” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Simoctocog alfa

-

All preparations”;

(lxxxiii)

lxxxiii

dengan memasukkan selepas butiran “Tadalafil” dan butir-butir yang berhubungan dengannya butiran yang berikut:

P.U. (A) 257 30

Names

Exempt

Group A

Group B

Group C

Group D

“Tafluprost

-

All preparations”;

(lxxxiv)

dengan memotong butiran “Tocilizumab” dan butir-butir yang berhubung dengannya;

(lxxxv)

dengan memotong butiran “Trastuzumab” dan butir-butir yang berhubung dengannya;

(lxxxvi)

dengan memasukkan selepas butiran “2, 2, 2-Trichloroethanol; esters of; their salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“3-

Trifluoromethylphenylpiperazine

(TFMPP)

-

All preparations”;

(lxxxvii)

lxxxvii

dengan memasukkan selepas butiran “Trioxsalen” dan butir-butir yang berhubungan dengannya butiran yang berikut:

P.U. (A) 257 31

Names

Exempt

Group A

Group B

Group C

Group D

“Triptorelin

-

All preparations”;

(lxxxviii)

lxxxviii

dengan memasukkan selepas butiran “Udenafil” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Ulinastatin

-

All preparations unless exempted

-

Naturally occurring ulinastatin”;

(lxxxix)

dengan memotong butiran “Ustekinumab” dan butir-butir yang berhubung dengannya;

(xc)

dengan memasukkan selepas butiran “Vecuronium; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

P.U. (A) 257 32

Names

Exempt

Group A

Group B

Group C

Group D

“Velpatasvir

-

All preparations”;

(xci)

dengan memotong butiran “Vedolizumab” dan butir-butir yang berhubung dengannya;

(xcii)

dengan memasukkan selepas butiran “Vemurafenib” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Venetoclax

-

All preparations”; dan

(xciii)

dengan memotong butiran “Zacyclonol; its salts” dan butir-butir yang berhubung dengannya; dan

(b)

dalam Lampiran kepada Senarai Racun—

(i)

dalam senarai “Analeptics and Central Stimulants:” —

(A)

dengan memasukkan selepas butiran “Cathinone (DD)” butiran “4-Chloromethcathinone”;

P.U. (A) 257 33

(B)

dengan memasukkan selepas butiran “2, 5-Dimethoxy-4-ethylamphetamine (DOET) (DD)” butiran

“Dimethylone”;

dengan memasukkan selepas butiran “Fluoroamphetamine (4-FA) (DD)” butiran “3-Fluoromethcathinone”;

(D)

dengan memasukkan selepas butiran “Leptazol” butiran “Lisdexamfetamine”;

(E)

dengan memasukkan selepas butiran

“Methiopropamine

(MPA)”

butiran

“5-Methoxy-N,N-diisopropyltryptamine”;

dengan memasukkan selepas butiran “5-Methoxy-3, 4-methylenedioxyamphetamine (MMDA) (DD)”

butiran berikut:

“5-Methoxy-N,N-methylisopropyltryptamine 4-Methyl-alpha-pyrrolidinobutiophenone 4-Methylbuphedrone”;

(G)

dengan memasukkan selepas butiran “4-Methylethcathinone (4-MEC)” butiran “Methyl (2S)-2-({1-[(4-

fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (AMB-FUBINACA)”;

(H)

dengan memasukkan selepas butiran “N-methyl-1-(3, 4-methylenedioxyphenyl)-2-butanamide (DD)” butiran

“Modafinil”; dan

P.U. (A) 257 34

dengan memasukkan selepas butiran “Strychnine” butiran “3-Trifluoromethylphenylpiperazine (TFMPP)”;

(ii)

dalam senarai “Analgesics including antipyretic and anti-inflammatory agents:”—

(A)

dengan memasukkan selepas butiran “Enphenamic acid; its salts” butiran “Erenumab”; dan

(B)

dengan memasukkan selepas butiran “Mesalazine” butiran “2-(2-Methoxyphenyl)-1-(1-pentylindol-3-

yl)ethanone (JWH-250)”;

(iii)

dalam senarai “Anti-asthmatics:”,—

dengan memasukkan selepas butiran “Bambuterol” butiran “Benralizumab”; dan dengan memasukkan selepas butiran “Indacaterol” butiran “Mepolizumab”;

(iv)

dalam senarai “Antidiabetics:” —

(A)

dengan memasukkan selepas butiran “Empagliflozin” butiran “Ertugliflozin”; dan

(B)

dengan memasukkan selepas butiran “Saxagliptin” butiran “Semaglutide”;

P.U. (A) 257 35

(v)

dalam senarai “Antifungals and Antiprotozoals:”—

(A)

dengan memasukkan selepas butiran “Imidocarb” butiran “Isavuconazole”; dan

(B)

dengan memasukkan selepas butiran “Secnidazole” butiran “Semduramicin”;

(vi)

dalam senarai “Antihistamines:”, dengan memasukkan selepas butiran “Cyproheptadine” butiran “Desloratadine”;

(vii)

dalam senarai “Antihypertensives:”, dengan memasukkan selepas butiran “Lacidipine” butiran “Lercanidipine”;

(viii)

dalam senarai “Antineoplastic agents and Immunosuppressants:”—

(A)

dengan memasukkan selepas butiran “Abatacept” butiran “Abemaciclib”;

(B)

dengan memasukkan selepas butiran “Afatinib” butiran “Alectinib”;

(C)

dengan memasukkan selepas butiran “Anastrozole” butiran “Apalutamide”;

(D)

dengan memasukkan selepas butiran “Azathioprine; its salts” butiran “Baricitinib”;

P.U. (A) 257 36

(E)

dengan memasukkan selepas butiran “Brentuximab” butiran berikut:

“Brigatinib

Brodalumab”;

(F)

dengan memasukkan selepas butiran “Cisplatin” butiran “Cladribine”;

(G)

dengan memasukkan selepas butiran “Gemcitabine, its salts” butiran “Guselkumab”;

(H)

dengan memasukkan selepas butiran “Irinotecan; its salts ” butiran berikut:

“Ixazomib

Ixekizumab”;

dengan memasukkan selepas butiran “Lomustine; its salts” butiran “Lorlatinib”;

dengan memasukkan selepas butiran “Necitumumab” butiran “Neratinib”;

(K)

dengan memasukkan selepas butiran “Regorafenib” butiran berikut:

“Ribociclib

Risankizumab”;

(L)

dengan memasukkan selepas butiran “Ruxolitinib” butiran “Sarilumab”;

P.U. (A) 257 37

(M)

dengan memasukkan selepas butiran “Semustine; its salts” butiran “Siltuximab”;

(N)

dengan memasukkan selepas butiran “Trimetrexate” butiran “Triptorelin”; dan

(O)

dengan memasukkan selepas butiran “Vemurafenib” butiran “Venetoclax”;

(ix)

dalam senarai “Antitubercular agents:”, dengan memasukkan selepas butiran “p-Aminosalicyclic acid and other substances structurally derived therefrom; their salts; their esters” butiran “Bedaquiline”;

(x)

dalam senarai “Antiviral agents:”—

(A)

dengan memasukkan selepas butiran “Atazanavir” butiran “Baloxavir marboxil”;

(B)

dengan memasukkan selepas butiran “Elbasvir” butiran “Elvitegravir”;

(C)

dengan memasukkan selepas butiran “Ganciclovir” butiran “Glecaprevir”;

(D)

dengan memasukkan selepas butiran “Ledipasvir” butiran “Letermovir”;

(E)

dengan memasukkan selepas butiran “Penciclovir” butiran “Pibrentasvir”; dan

P.U. (A) 257 38

(F)

dengan memasukkan selepas butiran “Valaciclovir; its salts” butiran “Velpatasvir”;

(xi)

dalam senarai “Hormones:”, dengan memotong butiran “ Zacyclonol; its salts”;

(xii)

dalam senarai “Narcotics”, dengan menggantikan butiran “Narcotic substances, the following: their isomers

(whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers (whenever the existence of such esters or ethers is possible); salts of their esters and ethers:”

dengan butiran “Narcotis substances; the followings:”;

(xiii)

dalam senarai “Tranquillisers:”, dengan memasukkan selepas butiran “Captodiamine; its salts” butiran “Cariprazine”;

(xiv)

dalam senarai “Vasolidators:”, dengan menggantikan butiran “ Sildenafil; its salts” dengan butiran “Sildenafil”; dan

(xv)

dalam senarai “Miscellaneous:”—

(A)

dengan memasukkan selepas butiran “Clopidogrel” butiran “Cobicistat”;

(B)

dengan memasukkan selepas butiran “Eltrombopag” butiran “Emicizumab”;

(C)

dengan memasukkan selepas butiran “Eptifibatide” butiran “Erdosteine”;

P.U. (A) 257 39

(D)

dengan memasukkan selepas butiran “Ergot, alkaloids of” butiran “Etelcalcetide”;

(E)

dengan memasukkan selepas butiran “Fluorides, alkali; organofluorides” butiran “Fluralaner”;

(F)

dengan memasukkan selepas butiran “Glucose” butiran “Glutathione”;

(G)

dengan memasukkan selepas butiran “Iomeprol” butiran “Iopamidol”;

(H)

dengan memasukkan selepas butiran “Lodoxamide tromethamine” butiran “Lonoctocog alfa”;

dengan memasukkan selepas butiran “Lovastatin” butiran “Lubiprostone”

dengan memasukkan selepas butiran “Rimonabant” butiran “Ripasudil”;

(K)

dengan memasukkan selepas butiran “Silodosin” dengan butiran “Simoctocog alfa”;

(L)

dengan memasukkan selepas butiran “Sumatriptan” butiran “Tafluprost”; dan

(M)

dengan memasukkan selepas butiran “L-Tryptophan” butiran “Ulinastatin”.

P.U. (A) 257 40

Dibuat 7 Ogos 2020

[KKM.R.600-1/1/56; PN(PU2)172/XVIII]

DATO’ SRI DR. ADHAM BIN BABA

Menteri Kesihatan

P.U. (A) 257 41

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) ORDER 2020

(a)

in the Poison List—

(i)

by deleting the item “Abciximab” and the particulars relating to it;

(ii)

by inserting after the item “Abatacept” and the particulars relating to it the following item:

P.U. (A) 257 42

Names

Exempt

Group A

Group B

Group C

Group D

“Abemaciclib

-

All preparations”;

(iii)

by deleting the item “Adalimumab” and the particulars relating to it;

(iv)

by inserting after the item “Alcuronium chloride” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Alectinib

-

All preparations”;

(v)

by deleting the item “Alemtuzumab” and the particulars relating to it;

(vi)

by deleting the item “Alirocumab” and the particulars relating to it;

(vii)

by substituting for the item “Allergens (in test kits)” and the particulars relating to it the following item:

P.U. (A) 257 43

Names

Exempt

Group A

Group B

Group C

Group D

“Allergens

-

(1)

All preparations for therapeutic use

(2)

In-vivo diagnostic test kits

-

(1)

All preparations unless in Group B

(2)

Preparation for laboratory use”;

(viii)

under “Antihistamines; the following:”, by inserting after the item “Cyproheptadine” the item “Desloratadine”:

(ix)

by inserting after the item “Antimony; its chlorides, oxides, sulphides, antimonates, antimonites; organic compounds of antimony ” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Apalutamide

-

All preparations”;

P.U. (A) 257 44

(x)

by deleting the item “Atezolizumab” and the particulars relating to it;

(xi)

by inserting after the item “Baclofen; its salts” and the particulars relating to it the following item:

Name

Exempt

Group A

Group B

Group C

Group D

“Baloxavir marboxil

-

All preparations”;

(xii)

by inserting after the item “Barbituric acid and other substances structurally derived therefrom; their compounds;

their salts” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Baricitinib

-

All preparations”;

(xiii)

by deleting the item “Basiliximab” and the particulars relating to it;

(xiv)

by inserting after the item “Beclamide” and the particulars relating to it the following item:

P.U. (A) 257 45

Names

Exempt

Group A

Group B

Group C

Group D

“Bedaquiline

-

All preparations”;

(xv)

by deleting the item “Belimumab” and the particulars relating to it;

(xvi)

by deleting the item “Bevacizumab” and the particulars relating to it;

(xvii)

by deleting the item “Blinatumomab” and the particulars relating to it;

(xviii)

by deleting the item “Brentuximab” and the particulars relating to it;

(xix)

by inserting after the item “Brexpiprazole” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Brigatinib

-

All preparations”;

(xx)

by deleting the item “Canakinumab” and the particulars relating to it;

P.U. (A) 257 46

(xxi)

by inserting after the item “Carfilzomib” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Cariprazine

-

All preparations”;

(xxii)

by deleting the item “Certolizumab” and the particulars relating to it;

(xxiii)

by deleting the item “Cetuximab” and the particulars relating to it;

(xxiv)

by inserting after the item “Chloroform” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“4-Chloromethcathinone

-

All preparations”;

(xxv)

by substituting for the item “Citicoline” and the particulars relating to it the following items:

P.U. (A) 257 47

Names

Exempt

Group A

Group B

Group C

Group D

“Citicoline

-

All preparations for parenteral administration

-

All preparations unless in

Group B

Cladribine

-

All preparations”;

(xxvi)

by inserting after the item “Clozapine” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Cobicistat

-

All preparations”;

(xxvii)

by deleting the item “Dacliximab” and the particulars relating to it;

(xxviii)

by deleting the item “Daratumumab” and the particulars relating to it;

(xxix)

by deleting the item “Denosumab” and the particulars relating to it;

P.U. (A) 257 48

(xxx)

by inserting after the item “Dimethyl fumarate” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Dimethylone

-

All preparations”;

(xxxi)

by deleting the item “Efalizumab” and the particulars relating to it;

(xxxii)

by inserting after the item “Eltrombopag” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Elvitegravir

-

All preparations”;

(xxxiii)

by inserting after the item “Eptifibatide” and the particulars relating to it the following item:

P.U. (A) 257 49

Names

Exempt

Group A

Group B

Group C

Group D

“Erdosteine

-

All preparations”;

(xxxiv)

by inserting after the item “Ertepenem sodium” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Ertugliflozin

-

All preparations”;

(xxxv)

by inserting after the item “Etanercept” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Etelcalcetide

-

All preparations”;

(xxxvi)

by deleting the item “Evolocumab” and the particulars relating to it;

P.U. (A) 257 50

(xxxvii)

by inserting after the item “4-Fluoroamphetamine (4-FA) (DD)” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“3-Fluoromethcathinone

-

All preparations”;

(xxxviii)

xxxviii

by inserting after the item “Fluoxetine; its salts” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Fluralaner

-

All preparations”;

(xxxix)

by inserting after the item “Glaphenine” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Glecaprevir

-

All preparations”;

P.U. (A) 257 51

(xl)

by inserting after the item “Glucose” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Glutathione

-

All preparations for parenteral administration

-

All preparations unless in Group C”;

(xli)

by deleting the item “Golimumab” and the particulars relating to it;

(xlii)

by deleting the item “Idarucizumab” and the particulars relating to it;

(xliii)

by deleting the item “Infliximab” and the particulars relating to it;

(xliv)

by inserting after the item “Iomeprol” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Iopamidol

-

All preparations”;

P.U. (A) 257 52

(xlv)

by inserting after the item “Irinotecan; its salts” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Isavuconazole

-

All preparations”;

(xlvi)

by inserting after the item “Ivermectin” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Ixazomib

-

All preparations”;

(xlvii)

by inserting after the item “Leptazol” and the particulars relating to it the following items:

Names

Exempt

Group A

Group B

Group C

Group D

“Lercanidipine

-

All preparations

Letermovir

-

All preparations”;

P.U. (A) 257 53

(xlviii)

by inserting after the item “Liraglutide” and the particulars relating to it the following items:

Names

Exempt

Group A

Group B

Group C

Group D

“Lisdexamphetamine

-

All preparations”;

(xlix)

by substituting for the item “Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:” and the items below it and the particulars relating to it the following items:

Names

Exempt

Group A

Group B

Group C

Group D

“Local anaesthetics; the following: their salts;

their homologues and analogues; their molecular compounds:

All preparations containing local anaesthetics unless in Group

B, Group C or

Group D

All preparations in pharmaceuti cal dosage forms unless in Group C

(1)

All preparations in pharmaceutical dosage form for topical use in the nose, eyes and ears or external use

Preparations for laboratory use”;

P.U. (A) 257 54

(2)

Suppositories, lozenges and pastilles

(3)

Preparations in the form of cartridges for dental use containing 2%

or less of local anaesthetic

Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or the derivatives of these acids;

their salts

Benzocaine

P.U. (A) 257 55

Bupivacaine

Butyl aminobenzoate

Cinchocaine

Diperodon

Etidocaine

Lignocaine

Levobupivacaine

Mepivacaine

Orthocaine

Oxethazaine

Phenacaine

Phenodianisyl

Prilocaine

Ropivacaine

Tetracaine

(l)

by inserting after the item “Lonazolac; its salts” and the particulars relating to it the following item:

P.U. (A) 257 56

Names

Exempt

Group A

Group B

Group C

Group D

“Lonoctocog alfa

-

All preparations”;

(li)

by inserting after the item “Lopinavir” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Lorlatinib

-

All preparations”;

(lii)

by inserting after the item “Lovastatin” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Lubiprostone

-

All preparations”;

(liii)

by inserting after the item “10-Methoxydeserpidine” and the particulars relating to it the following item:

P.U. (A) 257 57

Names

Exempt

Group A

Group B

Group C

Group D

“5-Methoxy-N,N-diisopropyltryptamine

-

All preparations”;

(liv)

by inserting after the item “5-Methoxy-3, 4 methylenedioxyamphetamine (MMDA) (DD)” and the particulars relating to it the following items:

Names

Exempt

Group A

Group B

Group C

Group D

“5-Methoxy-N,N-methylisopropyltryptamine

-

All preparations

2-(2-Methoxyphenyl)-1-(1-

pentylindol-3-yl)ethanone

(JWH-250)

-

All preparations

4-Methyl-alpha-pyrrolidinobutiophenone

-

All preparations”;

P.U. (A) 257 58

(lv)

by inserting after the item “Methyl bromide” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“4-Methylbuphedrone

-

All preparations”;

(lvi)

by inserting after the item “Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl] carbonyl}amino)-3-methylbutanoate

(5F-AMB)” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Methyl (2S)-2-({1-[(4-

fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-

methylbutanoate (AMB-FUBINACA)

-

All preparations”;

(lvii)

by inserting after the item “Moclobemide” and the particulars relating to it the following item:

P.U. (A) 257 59

Names

Exempt

Group A

Group B

Group C

Group D

“Modafinil

-

All preparations”;

(lviii)

by inserting after the item “Monensin” and the particulars relating to it the following items:

Names

Exempt

Group A

Group B

Group C

Group D

“Monoclonal antibody; includes the followings:

Abciximab

Adalimumab

Alemtuzumab

Alirocumab

Atezolizumab

Basiliximab

Belimumab

Benralizumab

-

All preparations”;

P.U. (A) 257 60

Bevacizumab

Blinatumomab

Brentuximab

Brodalumab

Canakinumab

Certolizumab

Cetuximab

Dacliximab

Daratumumab

Denosumab

Efalizumab

Emicizumab

Erenumab

Evolocumab

Golimumab

Guselkumab

Idarucizumab

Infliximab

Ixekizumab

Mepolizumab

Natalizumab

P.U. (A) 257 61

Necitumumab

Nivolumab

Obinutuzumab

Ofatumumab

Omalizumab

Palivizumab

Panitumumab

Pembrolizumab

Pertuzumab

Ramucirumab

Ranibizumab

Risankizumab

Rituximab

Sarilumab

Secukinumab

Tocilizumab

Trastuzumab

Ustekinumab

Vedolizumab

P.U. (A) 257 62

(lix)

by substituting for the item “Narcotic substances, the following: their isomers (whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers

(whenever the existence of such esters or ethers is possible); the salts of their esters and ethers -” the item

“Narcotic substances; the following:”;

(lx)

by deleting the item “Natalizumab” and the particulars relating to it;

(lxi)

by deleting the item “Necitumumab” and the particulars relating to it;

(lxii)

by inserting after the item “Nepafenec” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Neratinib

-

All preparations”;

(lxiii)

by substituting for the item “Nitric Oxide” and the particulars relating to it the following item:

P.U. (A) 257 63

Names

Exempt

Group A

Group B

Group C

Group D

“Nitric Oxide

-

Preparations in the form of medicinal gas for therapeutic use

-

All preparations unless in

Group B”;

(lxiv)

by deleting the item “Nivolumab” and the particulars relating to it;

(lxv)

by deleting the item “Obinutuzumab” and the particulars relating to it;

(lxvi)

by deleting the item “Ofatumumab” and the particulars relating to it;

(lxvii)

by deleting the item “Omalizumab” and the particulars relating to it;

(lxviii)

by deleting the item “Palivizumab” and the particulars relating to it;

(lxix)

by deleting the item “Panitumumab” and the particulars relating to it;

(lxx)

by deleting the item “Pembrolizumab” and the particulars relating to it;

P.U. (A) 257 64

(lxxi)

by deleting the item “Pertuzumab” and the particulars relating to it;

(lxxii)

by substituting for the item “Phenytoin and other substances structurally derived from hydantoin; their salts” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Phenytoin and other substances structurally derived from hydantoin;

their salts

-

All preparations unless exempted

-

Cosmetic which is notified under the Control of

Drugs and

Cosmetics

Regulations 1984

containing derivatives of hydantoin”;

(lxxiii)

by inserting after the item “Phosphorus white, yellow, red or black” and the particulars relating to it the following item:

P.U. (A) 257 65

Names

Exempt

Group A

Group B

Group C

Group D

“Pibrentasvir

-

All preparations”;

(lxxiv)

by deleting the item “Ramucirumab” and the particulars relating to it;

(lxxv)

by deleting the item “Ranibizumab” and the particulars relating to it;

(lxxvi)

by inserting after the item “Ribavirin” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Ribociclib

-

All preparations”;

(lxxvii)

by inserting after the item “Riociguat” and the particulars relating to it the following item:

P.U. (A) 257 66

Names

Exempt

Group A

Group B

Group C

Group D

“Ripasudil

-

All preparations”;

(lxxviii)

lxxviii

by deleting the item “Rituximab” and the particulars relating to it;

(lxxix)

by deleting the item “Secukinumab” and the particulars relating to it;

(lxxx)

by inserting after the item “Selexipag” and the particulars relating to it the following items:

Names

Exempt

Group A

Group B

Group C

Group D

"Semaglutide

-

All preparations

Semduramicin

-

All preparations”;

(lxxxi)

by substituting for the item “Sildenafil; its salts” and the particulars relating to it the following items:

P.U. (A) 257 67

Names

Exempt

Group A

Group B

Group C

Group D

“Sildenafil

-

All preparations

Siltuximab

-

All preparations”;

(lxxxii)

by inserting after the item “Simeprevir” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Simoctocog alfa

-

All preparations”;

(lxxxiii)

lxxxiii

by inserting after the item “Tadalafil” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Tafluprost

-

All preparations”;

P.U. (A) 257 68

(lxxxiv)

by deleting the item “Tocilizumab” and the particulars relating to it;

(lxxxv)

by deleting the item “Trastuzumab” and the particulars relating to it;

(lxxxvi)

by inserting after the item “2, 2, 2-Trichloroethanol; esters of; their salts” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“3-Trifluoromethylphenylpiperazine

(TFMPP)

-

All preparations”;

(lxxxvii)

lxxxvii

by inserting after the item “Trioxsalen” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Triptorelin

-

All preparations”;

(lxxxviii)

lxxxviii

by inserting after the item “Udenafil” and the particulars relating to it the following item:

P.U. (A) 257 69

Names

Exempt

Group A

Group B

Group C

Group D

“Ulinastatin

-

All preparations unless exempted

-

Naturally occurring ulinastatin”;

(lxxxix)

by deleting the item “Ustekinumab” and the particulars relating to it;

(xc)

by inserting after the item “Vecuronium; its salts” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Velpatasvir

-

All preparations”;

(xci)

by deleting the item “Vedolizumab” and the particulars relating to it;

(xcii)

by inserting after the item “Vemurafenib” and the particulars relating to it the following item:

P.U. (A) 257 70

Names

Exempt

Group A

Group B

Group C

Group D

“Venetoclax

-

All preparations”; and

(xciii)

by deleting the item “Zacyclonol; its salts” and the particulars relating to it; and

(b)

in the Appendix to the Poisons List—

(i)

in the list of “Analeptics and Central Stimulants:” —

(A)

by inserting after the item “Cathinone (DD)” the item “4-Chloromethcathinone”;

(B)

by inserting after the item “2, 5-Dimethoxy-4-ethylamphetamine (DOET) (DD)” the item “Dimethylone”;

by inserting after the item “Fluoroamphetamine (4-FA) (DD)” the item “3-Fluoromethcathinone”;

(D)

by inserting after the item “Leptazol” the item “Lisdexamfetamine”;

(E)

by inserting after the item “Methiopropamine (MPA)” the item “5-Methoxy-N,N-diisopropyltryptamine”;

P.U. (A) 257 71

by inserting after the item “5-Methoxy-3, 4-methylenedioxyamphetamine (MMDA) (DD)” the following items:

“5-Methoxy-N,N-methylisopropyltryptamine 4-Methyl-alpha-pyrrolidinobutiophenone 4-Methylbuphedrone”;

(G)

by inserting after the item

“4-Methylethcathinone

(4-MEC)”

the item

“Methyl

(2S)

-2-({1-[(4-

fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (AMB-FUBINACA)”;

(H)

by inserting after the item “N-methyl-1-(3, 4-methylenedioxyphenyl)-2-butanamide (DD)” the item “Modafinil”;

and by inserting after the item “Strychnine” the item “3-Trifluoromethylphenylpiperazine (TFMPP)”;

(ii)

in the list of “Analgesics including antipyretic and anti-inflammatory agents:” —

(A)

by inserting after the item “Enphenamic acid; its salts” the item “Erenumab”; and

(B)

by inserting after the item “Mesalazine” the item “2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-

250)”;

(iii)

in the list of “Anti-asthmatics:” —

P.U. (A) 257 72

by inserting after the item “Bambuterol” the item “Benralizumab”; and by inserting after the item “Indacaterol” the item “Mepolizumab”;

(iv)

in the list of “Antidiabetics:” —

(A)

by inserting after the item “Empagliflozin” the item “Ertugliflozin”; and

(B)

by inserting after the item “Saxagliptin” the item “Semaglutide”;

(v)

in the list of “Antifungals and Antiprotozoals:”—

(A)

by inserting after the item “Imidocarb” the item “Isavuconazole”; and

(B)

by inserting after the item “Secnidazole” the item “Semduramicin”;

(vi)

in the list of “Antihistamines:”, by inserting after the item “Cyproheptadine” the item “Desloratadine”;

(vii)

in the list of “Antihypertensives:”, by inserting after the item “Lacidipine” the item “Lercanidipine”;

(viii)

in the list of “Antineoplastic agents and Immunosuppressants:”—

P.U. (A) 257 73

(A)

by inserting after the item “Abatacept” the item “Abemaciclib”;

(B)

by inserting after the item “Afatinib” the item “Alectinib”;

(C)

by inserting after the item “Anastrozole” the item “Apalutamide”;

(D)

by inserting after the item “Azathioprine; its salts” the item “Baricitinib”;

(E)

by inserting after the item “Brentuximab” the following items:

“Brigatinib

Brodalumab”;

(F)

by inserting after the item “Cisplatin” the item “Cladribine”;

(G)

by inserting after the item “Gemcitabine, its salts” the item “Guselkumab”;

(H)

by inserting after the item “Irinotecan; its salts ” the following items:

“Ixazomib

Ixekizumab”;

by inserting after the item “Lomustine; its salts” the item “Lorlatinib”;

P.U. (A) 257 74

by inserting after the item “Necitumumab” the item “Neratinib”;

(K)

by inserting after the item “Regorafenib” the following items:

“Ribociclib

Risankizumab”;

(L)

by inserting after the item “Ruxolitinib” the item “Sarilumab”;

(M)

by inserting after the item “Semustine; its salts” the item “Siltuximab”;

(N)

by inserting after the item “Trimetrexate” the item “Triptorelin”; and

(O)

by inserting after the item “Vemurafenib” the item “Venetoclax”;

(ix)

in the list of “Antitubecular agents:”, by inserting after the item “p-Amino salicyclic acid and other substances structurally derived therefrom; their salts; their esters” the item “Bedaquiline”;

(x)

in the list of “Antiviral agents:”—

by inserting after the item “Atazanavir” the item “Baloxavir marboxil”;

P.U. (A) 257 75

by inserting after the item “Elbasvir” the item “Elvitegravir”;

by inserting after the item “Ganciclovir” the item “Glecaprevir”;

(D)

by inserting after the item “Ledipasvir” the item “Letermovir”;

(E)

by inserting after the item “Penciclovir” the item “Pibrentasvir”; and by inserting after the item “Valaciclovir; its salts” the item “Velpatasvir”;

(xi)

in the list of “Hormones:”, by deleting the item “Zacyclonol; its salts”;

(xii)

in the list of “Narcotics:”, by substituting for the item “Narcotic substances, the following: their isomers (whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers

(whenever the existence of such esters or ethers is possible); salts of their esters and ethers:” the item “Narcotic substances; the following:”;

(xiii)

in the list of “Tranquillisers:”, by inserting after the item “Captodiamine; its salts” the item “Cariprazine”;

(xiv)

in the list of “Vasolidators:”, by substituting for the item “ Sildenafil; it salts” the item “Sildenafil”; and

P.U. (A) 257 76

(xv)

in the list of “Miscellaneous:”—

by inserting after the item “Clopidogrel” the item “Cobicistat”;

by inserting after the item “Eltrombopag” the item “Emicizumab”;

by inserting after the item “Eptifibatide” the item “Erdosteine”;

(D)

by inserting after the item “Ergot, alkaloids of” the item “Etelcalcetide”;

(E)

by inserting after the item “Fluorides, alkali; organofluorides” the item “Fluralaner”;

by inserting after the item “Glucose” the item “Glutathione”;

(G)

by inserting after the item “Iomeprol” the item “Iopamidol”;

(H)

by inserting after the item “Lodoxamide tromethamine” the item “Lonoctocog alfa”;

by inserting after the item “Lovastatin” the item “Lubiprostone”

by inserting after the item “Rimonabant” the item “Ripasudil”;

P.U. (A) 257 77

(K)

by inserting after the item “Silodosin” the item “Simoctocog alfa”;

(L)

by inserting after the item “Sumatriptan” the item “Tafluprost”; and

(M)

by inserting after the item “L-Tryptophan” the item “Ulinastatin”.

Made 7 August 2020

[KKM.R.600-1/1/56; PN(PU2)172/XVIII]

DATO’ SRI DR. ADHAM BIN BABA

Minister of Health

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2020

About this p.u. (a)

(a)

(i)

(ii)

Part I

Part II

(iii)

(iv)

(v)

(vi)

(vii)

(1)

(2)

(1)

(2)

(viii)

(ix)

(x)

(xi)

(xii)

(xiii)

(xiv)

(xv)

(xvi)

(xvii)

(xviii)

(xix)

(xx)

(xxi)

(xxii)

(xxiii)

(xxiv)

(xxv)

(xxvi)

(xxvii)

(xxviii)

(xxix)

(xxx)

(xxxi)

(xxxii)

(xxxiii)

(xxxiv)

(xxxv)

(xxxvi)

(xxxvii)

(xxxviii)

(xxxix)

(xl)

(xli)

(xlii)

(xliii)

(xliv)

(xlv)

(xlvi)

(xlvii)

(xlviii)

(xlix)

Part II Exempt

(1)

(2)

(3)

(l)

(li)

(lii)

(liii)

(liv)

(lv)

(lvi)

(lvii)

(lviii)

(lix)

(lx)

(lxi)

(lxii)

(lxiii)

(lxiv)

(lxv)

(lxvi)

(lxvii)